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Abstract
Background: The potential use of microorganisms as agents of biological warfare (BW) is a
growing concern. Lassa virus, a member of the Arenavirus class of Hemorrhagic fever (HF) viruses
has emerged as a worldwide concern among public health officials. The purpose of the present
study was to further elucidate the antiviral activity spectrum of stampidine, a novel nucleoside
analog with potent anti-viral activity against the immunodeficiency viruses HIV-1, HIV-2, and FIV,
by examining its effects on survival of mice challenged with Lassa virus.
Methods:  We examined the therapeutic effect of Stampidine in CBA mice inoculated with
intracerebral injections of the Josiah strain of Lassa virus. Mice were treated either with vehicle or
nontoxic doses of stampidine administered intraperitoneally 24 hours prior to, 1 hour prior to, and
24 hours, 48 hours, 72 hours, and 96 hours after virus inoculation.
Results: The probability of survival following the Lassa challenge was significantly improved for
stampidine treated mice (Kaplan Meier, Chi-squared = 11.7, df = 2, Log-Rank p-value = 0.003).
Conclusion: Therefore, stampidine shows clinical potential as a new agent for treatment of viral
hemorrhagic fevers caused by Lassa virus.
Background
The potential use of microorganisms as agents of biologi-
cal warfare (BW) is a growing concern for several reasons,
including ease of production and dispersion, delayed
onset, ability to cause high rates of morbidity and mortal-
ity, difficulties in rapid diagnosis, and very limited treat-
ment options [1]. Biological agents that have been
identified as posing the greatest threat are variola major
(smallpox), Bacillus anthracis (anthrax), Yersinia pestis
(plague), Clostridium botulinum toxin (botulism), Fran-
cisella tularensis (tularaemia), and hemorrhagic fever
viruses [1]. Viral hemorrhagic fevers (VHF) are virus-
induced potentially fatal acute febrile, hemorrhagic dis-
eases reported from wide areas of the world. Hemorrhagic
fever (HF) viruses are enveloped, single-stranded RNA
viruses that are associated with insect or rodent vectors
whose interaction with humans defines the mode of dis-
ease transmission. There are 14 HF viruses, which belong
to four viral families: Arenaviridae, Bunyaviridae, Filoviri-
dae and Flaviviridae [2]. Arenaviruses are single-stranded
RNA viruses and show a predilection for rodents as virus
reservoirs [3,4]. This virus family includes lymphocytic
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choriomeningitis (LCM) virus, Lassa virus, and the Tacar-
ibe complex of viruses [3,4]. Pathogenic arenoviruses
have been identified as the causative agents in Argentine
HF (virus: Junin), Bolivian HF (virus: Machupo), Vene-
zuelan HF (virus: Guanarito), Brazilian HF (virus: Sabia),
lymphocytic choriomeningitis (LCM) (virus: LCM), and
Lassa fever (virus: Lassa) [5-10]. The family prototype,
LCM virus, was first isolated in 1933 from material of a
patient who died during the first documented epidemic of
St. Louis encephalitis [5].
Lassa fever is an acute viral disease found in many coun-
tries of West Africa from Nigeria to Senegal, which causes
considerable morbidity and mortality [11-14]. Lassa was
initially discovered in a Nigerian hospital in the Lassa vil-
lage when several nurses developed the illness [11]. Noso-
comial outbreaks have since occurred in Nigeria, Liberia,
and Sierra Leone, and Lassa fever has also been encoun-
tered in United Kingdom, Germany, Japan, Canada, Israel
and the United States [6,11-21]. Severe multi-organ
involvement occurs in 5–10% of infections and case-fatal-
ity rates for hospitalized patients range from 15 to 25%
[22,23]. It has also been shown to be the cause of prema-
ture births and spontaneous abortions in pregnant
women. The virus is transmitted by the respiratory route
and by direct contact with contaminated materials.
Because of the ability of Lassa virus to spread from person
to person, risk of its importation by international travel,
and renewed threats about the potential use of HF viruses
for BW, Lassa fever has emerged as a worldwide concern
among public health officials [24]. The high incidence
and severity of pediatric Lassa fever is of particular con-
cern: A systematic study of Lassa fever in febrile children
was undertaken over a four-year period, from August
1977 to August 1981, in the Eastern Province of Sierra
Leone, West Africa. 479 patients were studied. Of these,
245 had adequate specimens to confirm or exclude the
laboratory diagnosis of Lassa fever. 51 cases of Lassa fever
were identified (21% of patients for whom diagnosis was
possible) [25]. Thirty-three cases of pediatric Lassa fever
were identified at Curran Lutheran Hospital and Phebe
Hospital in Liberia between January 1980 and March
1984. All 18 fetal cases died and the case-fatality rate for
15 childhood cases was 27% [26].
Stampidine (STAMP), stavudine-5'-[p-bromophenyl
methoxyalaninyl phosphate], is a novel nucleoside ana-
log with potent anti-viral activity against the immunode-
ficiency viruses HIV-1, HIV-2, and FIV, which may provide
the basis for effective salvage therapies for patients harbor-
ing highly drug resistant strains of HIV-1 [27]. Stampidine
exhibits potent in vitro antiretroviral activity against pri-
mary clinical HIV-1 isolates with genotypic and pheno-
typic NRTI-resistance, clinical HIV-1 isolates of non-B
envelope subtype originating from South America, Asia,
and sub-Saharan Africa, as well as NNRTI-resistant HIV
with nanomolar IC50 values [28]. We previously investi-
gated the in vivo pharmacokinetics, metabolism, toxicity,
and antiretroviral activity of STAMP in rodent species
[29,30]. In mice and rats, STAMP was very well tolerated
without any detectable acute or subacute toxicity at single
intrapertitoneal or oral bolus dose levels as high as 500
mg/kg [30]. Notably, daily administration of STAMP
intraperitoneally or orally for up to 8 consecutive weeks
was not associated with any detectable toxicity in mice or
rats at cumulative dose levels as high as 6.4 g/kg [30].
STAMP exhibited potent in vivo anti-HIV activity in Hu-
PBL-SCID mice at nontoxic dose levels [31]. In accordance
with its safety profile in rodent species, a four-week stam-
pidine treatment course with twice daily administration
of hard gelatin capsules containing 25 mg/kg – 100 mg/kg
stampidine was very well tolerated by dogs and cats at
cumulative dose levels as high as 8.4 g/kg [32]. A 4-week
treatment course with STAMP administered in gelatin cap-
sules twice daily showed a dose-dependent antiretroviral
effect in chronically feline immunodeficiency virus (FIV)-
infected cats, as evidenced by a ≥1-log decrease of the FIV
load of circulating peripheral blood mononuclear cells
within 2 weeks after initiation of STAMP therapy [32]. The
antiviral activity of stampidine is not limited to HIV and
FIV. Stampidine was also found to inhibit adenovirus-
induced plaque formation in skin fibroblasts at nanomo-
lar concentrations [33].
The purpose of the present study was to further elucidate
the antiviral activity spectrum of stampidine by examin-
ing its effects on survival of mice challenged with Lassa
virus.
Methods
Stampidine
The synthetic procedures for preparation of Stampidine
[2',3'-didehydro-3'-deoxythymidine 5'-(p-bromophenyl
methoxyalaninyl phosphate)] (STAMP) have been previ-
ously described in detail [34,35].
Animal infection
Animal infection was performed in an appropriate Ani-
mal BioSafety Level-3 Laboratory (ABL-3) at BRIEM
(Research Institute for Epidemiology and Microbiology,
MINSK, Belarus) with the technician wearing appropriate
facility clothing. The culture was thawed in a water bath at
37°C and then diluted in normal saline to achieve the
required concentration. In this study, all mice were chal-
lenged with 1000 PFU which is 100-times higher than the
LD50 dose. Each group of animals was placed in a sepa-
rate cage. (It should be noted that Lassa virus in the
United States is considered a BioSafety Level 4 pathogen.)BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/1
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Lassa virus model
CBA strain mice were intracerebrally infected with 1000
PFU of Lassa virus (Josiah strain) that resulted in lethality
of 80–100% of control (non-treated) animals in 7–9 days
after infection. Control animals were given physiologic
salt solution as a placebo instead of the compound. In
general, for non-treated animals, clinical signs of the dis-
ease manifested on the 5th and 7th days by presenting:
weight loss, immobility, disheveled hair, convulsions,
severe decubitus paralysis and death. All subjective meas-
urement of decreased mobility and scruffy fur were done
in a blinded fashion as not to influence the results. The
protective properties of the experimental antiviral drugs
were assessed by using the following treatment-preventa-
Table 1: Anti-LASSA Activity of Stampidinc in CBA mice
Disease Onset (Days After Inoculation with Lassa Virus)
Decreased mobility Scruffy Fur Convulsions Weight Loss (%) Survival (days)
Group A – Vehicle
M o u s e  # 1 * N AN AN AN A≤ 1
M o u s e  # 2 * N AN AN AN A≤ 1
Mouse #3 6.0 6.0 7.0 4.5 8
Mouse #4 6.0 6.5 8.0 5.0 9
Mouse #5 7.5 7.0 8.0 9.0 9.5
Mouse #6 7.5 7.5 8.0 4.3 9.0
Mouse #7 7.0 7.0 8.0 4.3 9.0
Mouse #8 7.0 7.0 8.5 4.5 9.5
Mouse #9 7.0 7.0 8.5 8.3 9.5
Mouse #10 7.0 7.0 8.5 4.8 9.5
Mouse #11 8.5 8.0 9.0 5.3 10.5
Mouse #12 8.5 8.0 9.0 4.5 10.0
Mouse #13 8.0 8.5 9.5 4.5 10.0
Mouse #14 9.0 9.0 10.5 4.1 11.0
Mouse #15 9.0 9.5 11.0 4.3 11.5
Mouse #16 9.0 10.0 NO NO >21
Mouse #17 9.0 10.0 NO NO >21
Mouse #18 9.0 10.0 11.0 NO >21
Mouse #19 9.0 10.0 NO NO >21
Mouse #20 9.5 10.0 NO NO >21
Group B – Stampidine 25 mg/kg
M o u s e  # 1 * N AN AN AN A≤ 1
M o u s e  # 2 * N AN AN AN A≤ 1
Mouse #3 6.0 6.0 7.5 4.3 8
Mouse #4 9.0 9.5 10.0 8.3 9.5
Mouse #5 9.5 10.0 NO NO >21
Mouse #6 9.5 10.0 NO NO >21
Mouse #7 10.0 9.5 NO NO >21
Mouse #8 9.0 10.0 NO NO >21
Mouse #9 10.0 10.0 NO NO >21
Mouse #10 8.5 9.5 NO NO >21
Group C – Stampidine 50 mg/kg
Mouse #1 13 13 NO 8.7 16
M o u s e  # 2 9 . 0N ON ON O> 2 1
Mouse #3 9.5 10.0 NO NO >21
Mouse #4 NO NO NO NO >21
Mouse #5 NO NO NO NO >21
Mouse #6 NO NO NO NO >21
Mouse #7 NO NO NO NO >21
Mouse #8 NO NO NO NO >21
Mouse #9 NO NO NO NO >21
M o u s e  # 1 0 N ON ON ON O> 2 1
*Mouse died after traumatic intracerebral injection; NA = not applicable; NO = not observedBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/1
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tive regimen: Mice were treated either with vehicle or
stampidine (25 mg/kg or 50 mg/kg) administered intra-
peritoneally 24 hours prior to, 1 hour prior to, and 24
hours, 48 hours, 72 hours, and 96 hours after virus inoc-
ulation. Mice were then observed for 21-days post infec-
tion. The protective effect of the experimental anti-viral
drugs was evaluated according to the rise of the survival
rate and prolongation of mean life of the experimental
animals as compared with the control animals.
Statistical Analysis
Statistical Significance was determined using the Kaplan
Meier Log-Rank test.
Results
In order to evaluate the anti-Lassa activity of stampidine,
CBA mice were inoculated with intracerebral injections of
the Josiah strain of Lassa [36] at a 1000 PFU dose level,
which is lethal to 70–100% of mice within 7–12 days
[37]. Mice were treated either with vehicle or stampidine
administered intraperitoneally 24 hours prior to, 1 hour
prior to, and 24 hours, 48 hours, 72 hours, and 96 hours
(Total number of doses administered to each mouse = 6)
after virus inoculation. Mice were then observed twice
daily for 21 days for morbidity and mortality. Of the 20
control mice, 2 died on day 1 immediately after intracere-
bral injection due to accidental brain injury and are not
available. All of the remaining 18 vehicle-treated control
mice developed decreased mobility and scruffy fur as the
clinical signs of Lassa infection between days 6 and 10
(Table 1). Fourteen of the 18 control mice developed sei-
zures between days 7 and 11. Thirteen mice experienced
4–10% weight loss and died between days 8 and 11
(Table 1, Figure 1). Of the 10 mice treated with stampi-
dine at the 25 mg/kg dose level, two died accidentally
immediately after intracerebral Lassa virus inoculation.
All of the remaining 8 mice developed decreased mobility
and scruffy fur as the clinical signs of Lassa infection
between days 6 and 10. Two of these mice experienced 4–
8% weight loss, developed seizures and died on days 8
and 10, respectively. The remaining 6 mice survived the
Lassa challenge beyond the 21-day observation period
and did not experience any weight loss or seizures (Table
1, Figure 1). Of the 10 mice treated with stampidine at the
50 mg/kg dose level, only one mouse developed delayed
signs of Lassa infection on day 13 as evidenced by
decreased mobility and scruffy fur, lost weight, and died
on day 16 after intracerebral Lassa virus inoculation. All 9
of the remaining mice remained healthy without clinical
signs of Lassa infection beyond the 21-day observation
period. The probability of survival following the Lassa
challenge was significantly improved for stampidine
treated mice (Kaplan Meier, Chi-squared = 11.7, df = 2,
Log-Rank p-value = 0.003): The probability of survival at
21 days was 28% (7–48%, 95% confidence limits) for
vehicle-treated mice (median survival = 9 days), 75%
(45–100%) for mice treated with stampidine at the 25
mg/kg dose level (median survival >21 days), and 90%
(72–100%) for mice treated with stampidine at the 50
mg/kg dose level (median survival >21 days).
Discussion
These results provide unprecedented evidence that stam-
pidine is active against Lassa fever virus and exhibits a
potent prophylactic effect when used at nontoxic dose lev-
els. Therefore, stampidine shows clinical potential as a
new agent for treatment of viral hemorrhagic fevers
caused by Lassa virus. In view of the growing concerns
about the possible use of HF viruses as BW agents, it will
be important to determine if stampidine has activity
against other viruses associated with lethal viral hemor-
rhagic fevers and/or encephelomyelitis, such as the Ebola
viruses of the Filoviridae family.
The previously documented in vitro and in vivo antiretro-
viral activity of stampidine against primary clinical HIV-1
isolates with genotypic and/or phenotypic NRTI-resist-
ance together with its favorable animal toxicity profile,
pharmacokinetics, and in vivo antiretroviral activity in FIV-
infected cats have prompted the further development of
this promising new NRTI compound as an anti-HIV agent.
Our results presented herein provide unprecedented
experimental evidence that stampidine exhibits antiviral
activity in the central nervous system (CNS) of Lassa virus-
infected mice. The ability of zidovudine prodrugs, such as
stampidine, to cross the blood-brain barrier have been
previously described [38]. Our previous experiments have
demonstrated that stampidine is rapidly metabolized to
its active form, ala-MP in plasma (> 95% within 5
mins)[29]. Thus, binding of stampidine to plasma pro-
teins is not a phenomenon that would interfere with effi-
cacy. These observations are relevant because HIV-1 also
infects the CNS and it has been feared that the CNS may
be a sanctuary site where HIV-1 could hide and continue
to replicate despite otherwise effective antiretroviral treat-
ment [39,40]. A variety of HIV-induced lesions of the CNS
have been described, including HIV encephalitis, HIV leu-
koencephalopathy, axonal damage, and diffuse
poliodystrophy with neuronal loss of variable severity
[41]. HIV-1 encephalitis and its associated dementia can
occur in up to 20% of infected individuals, usually when
productive viral replication in brain mononuclear phago-
cytes (macrophages and microglia) and depletion of
CD4(+) T lymphocytes are most significant [42,43].
Hence, antiretroviral treatment of HIV-infected persons
should include agents with potent activity in the CNS
[44]. Our results support the notion that stampidine may
be useful for inhibition of HIV replication in the CNS.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/1
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Conclusions
Lassa fever has emerged as a worldwide concern among
public health officials because of the ability of Lassa virus
to spread from person to person, risk of its importation by
international travel, and renewed threats about the poten-
tial use of HF viruses for biological warfare. Given the
need for an anti-viral agent to treat patients with Lassa
fever, we examined the therapeutic potential of Stampi-
dine, a novel nucleoside analog with potent anti-viral
activity against the immunodeficiency viruses HIV-1, HIV-
2, and FIV, in Lassa-infected mice. Treatment with stampi-
dine significantly improved the probability of survival fol-
lowing the Lassa challenge. Therefore, stampidine shows
clinical potential as a new agent for treatment of viral
hemorrhagic fevers caused by Lassa virus. In this first
study, mice were treated with 6 doses of stampidine and 2
of the treatments were administered prior to virus inocu-
lation. The elucidation of optimized prophylactic as well
as post-exposure treatment regimens will be the focus of
our future studies.
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Protective Activity of Stampidine in CBA Mice Challenged with Lassa Virus Figure 1
Protective Activity of Stampidine in CBA Mice Challenged with Lassa Virus. CBA mice were inoculated with intrac-
erebral injections of the Josiah strain of Lassa at a 1000 PFU dose level. Mice were treated either with vehicle or stampidine (25 
mg/kg or 50 mg/kg) administered intraperitoneally 24 hours prior to, 1 hour prior to, and 24 hours, 48 hours, 72 hours, and 96 
hours after virus inoculation. Mice were then observed twice daily for 21 days for morbidity and mortality. Results are pre-
sented as the cumulative proportion of mice surviving after virus inoculation. See Table 1 for more detailed information of the 
treatment outcome.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/1
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